Company intelligence / Profile preview
LinqMed
Chuo-ku, Tokyo, Japanlinqmed.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LinqMed’s lead radiotherapeutic, 64Cu–ATSM, selectively accumulates in hypoxic tumor cells and is currently in Phase III clinical trials for malignant brain tumors. The company is pioneering the use of copper radioisotope 64Cu to combine diagnosis and therapy (“Visible Cancer Therapeutics”) on a single platform. Early results suggest high selectivity for hypoxic cancer cells with potential to address treatment-resistant cancers such as glioblastoma. The company has received recognition from major Japanese innovation programs and has secured Series A funding.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall moleculePeptidesAntibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
PDRadiopharma Inc. (strategic manufacturing/distribution partnership in Japan)
Beyond the preview
Go deeper on LinqMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LinqMed.